問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

Recruiting

List

900Cases

2021-07-21 - 2023-03-29

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2022-04-01 - 2028-02-28

Phase III

An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer

  • Condition/Disease

    Colorectal Neoplasms

  • Test Drug

    Tucatinib

Participate Sites
5Sites

Recruiting5Sites

2017-03-01 - 2020-06-30

Phase III

A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20mg Compared to Lansoprazole 30mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter Pylori Infection

  • Condition/Disease

    Gastric Ulcer

  • Test Drug

    TAK-438

Participate Sites
6Sites

Recruiting5Sites

邱正堂
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2017-03-14 - 2025-05-13

Phase II

An Open-Label, Multicenter, Global Phase 2 Basket Study of for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Entrectinib Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

  • Condition/Disease

    Locally Advanced or Metastatic Solid Tumors that Entrectinib Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

  • Test Drug

    Entrectinib

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

羅永鴻
Taipei Veterans General Hospital

2016-11-01 - 2019-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2020-02-01 - 2021-09-15

Phase III

A Phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis.

  • Condition/Disease

    generalized myasthenia gravis

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Recruiting5Sites

郭育呈
China Medical University Hospital

Division of Neurology

2019-09-01 - 2022-09-22

Phase III

A double-blind, placebo-controlled,randomized withdrawal, multicenter clinical trial evaluating the efficacy, safety, and tolerability of cariprazine in a dose-reduction paradigm in the prevention of relapse in bipolar I disorder patients whose current episode is manic or depressive, with or without mixed features

  • Condition/Disease

    Bipolar I disorder

  • Test Drug

    Cariprazine

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2021-05-20 - 2023-05-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-10-20 - 2022-04-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2020-04-27 - 2022-04-27

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of the Efficacy and Safety of Lemborexant in Chinese Subjects with Insomnia Disorder

  • Condition/Disease

    Insomnia Disorder

  • Test Drug

    Lemborexant

Participate Sites
2Sites

Recruiting2Sites

1 84 85 86 87 88 90
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB